{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:02:37Z","timestamp":1789851757832,"version":"4.0.1"},"reference-count":158,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","award":["no number"],"award-info":[{"award-number":["no number"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"award":["no number"],"award-info":[{"award-number":["no number"]}],"id":[{"id":"https:\/\/ror.org\/01qpw1b93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic inflammatory skin diseases, including psoriasis, hidradenitis suppurativa (HS), and atopic dermatitis (AD), are increasingly recognized as systemic disorders associated with chronic immune dysregulation. Growing evidence supports their links with metabolic disorders, reflected in heightened interest in therapeutic strategies targeting the immunometabolic axis. This review summarizes current knowledge on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the regulation of immune and metabolic processes in chronic inflammatory skin diseases, with particular emphasis on molecular mechanisms and available experimental and clinical data. GLP-1RAs, widely used in the treatment of type 2 diabetes and obesity, may also exhibit anti-inflammatory and immunomodulatory properties beyond their classical metabolic effects. GLP-1 signalling can influence keratinocyte function, immune cell activity, and wound healing. Furthermore, it modulates multiple intracellular signalling pathways, including cAMP\/PKA, AMPK, PI3K\/Akt, and NF-\u03baB, as well as immune axes such as IL-23\/Th17\/IL-17 and inflammasome-related signalling. Available evidence suggests that GLP-1RAs may reduce inflammation and disease activity in selected inflammatory dermatoses. However, current evidence remains limited and is based primarily on experimental studies, case reports, and small-scale observational studies. Further well-designed clinical trials are needed to better define the therapeutic potential of GLP-1RAs and their role in dermatological practice.<\/jats:p>","DOI":"10.3390\/pharmaceutics18050605","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:39:34Z","timestamp":1779295174000},"page":"605","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5660-2143","authenticated-orcid":false,"given":"Klara","family":"Andrzejczak","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9100-9321","authenticated-orcid":false,"given":"Emilia","family":"Kucharczyk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8265-406X","authenticated-orcid":false,"given":"Matylda","family":"Korgiel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5306-7048","authenticated-orcid":false,"given":"Justyna","family":"Drozdowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Maj","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ponikowska","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tripathy, K., Dulai, A.S., Min, M., and Sivamani, R.K. (2026). Insulin Resistance, Metabolic Syndrome, and Inflammatory Skin Disease. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010330"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Xia, J., Ding, L., and Liu, G. (2025). Metabolic Syndrome and Dermatological Diseases: Association and Treatment. Nutr. Metab., 22.","DOI":"10.1186\/s12986-025-00924-1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/bjd\/ljaf153","article-title":"Outcome Measures for Interdisciplinary Care in Immune-Mediated Inflammatory Skin Diseases: A Scoping Review","volume":"193","author":"Lemarcq","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Campanati, A., Martina, E., and Offidani, A. (2022). The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going. Biomedicines, 10.","DOI":"10.3390\/biomedicines10050950"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdin.2025.07.003","article-title":"Decreased Incidence of Hidradenitis Suppurativa and Psoriasis in Diabetic Patients Treated with GLP-1 Receptor Agonists: A Retrospective Cohort Study","volume":"22","author":"Ching","year":"2025","journal-title":"JAAD Int."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Deng, S., Chen, Z., and Shi, Y. (2025). Roles of Glucagon-like Peptide 1 Receptor Agonists in Immune Cell Biology and Autoimmune\/Autoinflammatory Diseases. Cell Biosci., 15.","DOI":"10.1186\/s13578-025-01486-8"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tassavor, B., and Al Salem, S. (2025). Use of Glucagon-like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review. Cureus, 17.","DOI":"10.7759\/cureus.93282"},{"key":"ref_8","unstructured":"Patino, W., Thomas, A., Jain, S., Del Rosso, J.Q., and Issa, N.T. (2025). A Review of Glucagon-like Peptide-1 in Dermatology. J. Clin. Aesthetic Dermatol., 18."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased Expression of Glucagon-like Peptide-1 Receptors in Psoriasis Plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","article-title":"GLP-1 Receptor Agonists as Emerging Modulators of Inflammation and Angiogenesis in Chronic Cutaneous Wound Healing","volume":"145","author":"Mehta","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent Updates on GLP-1 Agonists: Current Advancements & Challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like Peptide-1 Analogue Liraglutide Facilitates Wound Healing by Activating PI3K\/Akt Pathway in Keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The Effects of GLP-1RA on Inflammatory Skin Diseases: A Comprehensive Review","volume":"39","author":"Paschou","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alharbi, S.H. (2024). Anti-Inflammatory Role of Glucagon-like Peptide 1 Receptor Agonists and Its Clinical Implications. Ther. Adv. Endocrinol. Metab., 15.","DOI":"10.1177\/20420188231222367"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like Peptide-1 Receptor Agonist Liraglutide Therapy for Psoriasis Patients with Type 2 Diabetes: A Randomized-Controlled Trial","volume":"33","author":"Lin","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central Glucagon-like Peptide 1 Receptor Activation Inhibits Toll-like Receptor Agonist-Induced Inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lazarowitz, R., Saroufim, L., Sauder, M., Osman, M., Tardio, V., Litvinov, I.V., and Netchiporouk, E. (2026). Glucagon-like Peptide-1 Receptor Agonists as Metabolic Adjuncts in Immune-Mediated Skin Disease. J. Am. Acad. Dermatol., ahead of print.","DOI":"10.1016\/j.jaad.2026.02.047"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4062\/biomolther.2020.054","article-title":"The Role of Leptin in the Association Between Obesity and Psoriasis","volume":"29","author":"Hwang","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cytogfr.2026.01.003","article-title":"Reprogramming Immunity at the Metabolic-Epidermal Interface in Obesity-Associated Psoriasis","volume":"88","author":"Jang","year":"2026","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin Hormones: Their Role in Health and Disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like Peptide-1-(7-36)Amide Is Transformed to Glucagon-like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon Duplication and Divergence in the Human Preproglucagon Gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The Physiology of Glucagon-like Peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like Peptide-1 Attenuates Bleomycin-Induced Pulmonary Fibrosis, Involving the Inactivation of NF-\u039aB in Mice","volume":"22","author":"Gou","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like Peptide-1 (GLP-1) and the Regulation of Human Invariant Natural Killer T Cells: Lessons from Obesity, Diabetes and Psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","article-title":"GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7","volume":"21","author":"Koehler","year":"2015","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., and Liu, X. (2015). Liraglutide Attenuates High Glucose-Induced Abnormal Cell Migration, Proliferation, and Apoptosis of Vascular Smooth Muscle Cells by Activating the GLP-1 Receptor, and Inhibiting ERK1\/2 and PI3K\/Akt Signaling Pathways. Cardiovasc. Diabetol., 14.","DOI":"10.1186\/s12933-015-0177-4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/B978-0-12-381517-0.00010-2","article-title":"Epac2-Dependent Rap1 Activation and the Control of Islet Insulin Secretion by Glucagon-like Peptide-1","volume":"84","author":"Leech","year":"2010","journal-title":"Vitam. Horm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of Action of Glucagon-like Peptide 1 in the Pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1172\/JCI42497","article-title":"Pancreatic GLP-1 Receptor Activation Is Sufficient for Incretin Control of Glucose Metabolism in Mice","volume":"122","author":"Lamont","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s004240050558","article-title":"Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1","volume":"435","author":"Gromada","year":"1998","journal-title":"Pflug. Arch."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/isl.3.3.15507","article-title":"Phospholipase C-\u03b5 Links Epac2 Activation to the Potentiation of Glucose-Stimulated Insulin Secretion from Mouse Islets of Langerhans","volume":"3","author":"Dzhura","year":"2011","journal-title":"Islets"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2002-0306","article-title":"Glucagon-like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis","volume":"17","author":"Drucker","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007995.2015.1103214","article-title":"The Value of Short- and Long-Acting Glucagon-like Peptide-1 Agonists in the Management of Type 2 Diabetes Mellitus: Experience with Exenatide","volume":"32","author":"Guo","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 Receptor Agonist Impairs Keratinocytes Inflammatory Signals by Activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like Peptide-1 Receptor and Proglucagon Expression in Mouse Skin","volume":"134","author":"List","year":"2006","journal-title":"Regul. Pept."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","article-title":"Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons","volume":"15","author":"Cedirian","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like Peptide 1 Induces Pancreatic Beta-Cell Proliferation via Transactivation of the Epidermal Growth Factor Receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fusco, J., Xiao, X., Prasadan, K., Sheng, Q., Chen, C., Ming, Y.C., and Gittes, G. (2017). GLP-1\/Exendin-4 Induces \u03b2-Cell Proliferation via the Epidermal Growth Factor Receptor. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-09898-4"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dvdy.20012","article-title":"Activation of Nestin-Positive Duct Stem (NPDS) Cells in Pancreas Upon Neogenic Motivation and Possible Cytodifferentiation into Insulin-Secreting Cells from NPDS Cells","volume":"230","author":"Kim","year":"2004","journal-title":"Dev. Dyn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1007\/s00018-004-4144-6","article-title":"Nestin Expression\u2014A Property of Multi-Lineage Progenitor Cells?","volume":"61","author":"Wiese","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","first-page":"161","article-title":"Liraglutide Attenuates Myocardial Ischemia\/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R\/PI3K\/Akt Pathway","volume":"23","author":"Zhou","year":"2023","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbrc.2018.10.197","article-title":"GLP-1RA Promotes Brown Adipogenesis of C3H10T1\/2 Mesenchymal Stem Cells via the PI3K-AKT-MTOR Signaling Pathway","volume":"506","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00403-007-0809-y","article-title":"The Role of Heparin-Binding EGF-like Growth Factor and Amphiregulin in the Epidermal Proliferation of Psoriasis in Cooperation with TNF\u03b1","volume":"300","author":"Yoshida","year":"2008","journal-title":"Arch. Dermatol. Res."},{"key":"ref_48","first-page":"497","article-title":"Expression, Subcellular Localization and Cytokinic Modulation of Toll-like Receptors (TLRs) in Normal Human Keratinocytes: TLR2 up-Regulation in Psoriatic Skin","volume":"17","author":"Begon","year":"2007","journal-title":"Eur. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in Psoriasis After Treatment with the Glucagon-like Peptide-1 Receptor Agonist Liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of Psoriasis during Glucagon-like Peptide-1 Analogue Therapy in Type 2 Diabetes Is Associated with Decreasing Dermal \u0393\u03b4 T-Cell Number: A Prospective Case-Series Study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s42000-025-00635-5","article-title":"GLP-1RAs in Patients with Psoriasis","volume":"24","author":"Paschou","year":"2025","journal-title":"Hormones"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like Peptide-1 Analogue Therapy for Psoriasis Patients with Obesity and Type 2 Diabetes: A Prospective Cohort Study","volume":"27","author":"Ahern","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"G\u00e1lvez, N.M.S., Bohmwald, K., Pacheco, G.A., Andrade, C.A., Carre\u00f1o, L.J., and Kalergis, A.M. (2020). Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases. Clin. Microbiol. Rev., 34.","DOI":"10.1128\/CMR.00232-20"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molimm.2018.09.023","article-title":"The Ins and Outs of Type I INKT Cell Development","volume":"105","author":"Shissler","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/eji.201847647","article-title":"Innate and Adaptive Stimulation of Murine Diverse NKT Cells Result in Distinct Cellular Responses","volume":"49","author":"Tripathi","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.4049\/jimmunol.1001829","article-title":"The Role of the Transcription Factor CREB in Immune Function","volume":"185","author":"Wen","year":"2010","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tian, S., Zhou, S., Wu, W., Lin, Y., Wang, T., Sun, H., A-Ni-Wan, A.S.J., Li, Y., Wang, C., and Li, X. (2025). GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via \u03b2-Klotho-Mediated Ferroptosis Inhibition. Adv. Sci., 12.","DOI":"10.1002\/advs.202409781"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mazzieri, A., Basta, G., Calafiore, R., and Luca, G. (2023). GLP-1 RAs and SGLT2i: Two Antidiabetic Agents Associated with Immune and Inflammation Modulatory Properties through the Common AMPK Pathway. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1163288"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1002\/jcp.30102","article-title":"Exenatide Improves Random-Pattern Skin Flap Survival via TFE3 Mediated Autophagy Augment","volume":"236","author":"Li","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Machida, A., Suzuki, K., Nakayama, T., Miyagi, S., Maekawa, Y., Murakami, R., Uematsu, M., Kitaoka, T., and Oishi, A. (2025). Glucagon-like Peptide 1 Receptor Agonist Stimulation Inhibits Laser-Induced Choroidal Neovascularization by Suppressing Intraocular Inflammation. Investig. Ophthalmol. Vis. Sci., 66.","DOI":"10.1167\/iovs.66.5.15"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjd.15014","article-title":"Interleukin-17 in Skin: Psoriasis and Yonder","volume":"175","author":"Puig","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjd.14703","article-title":"The Many Faces of Interleukin-17 in Inflammatory Skin Diseases","volume":"175","author":"Speeckaert","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","article-title":"Glucagon-like Peptide-1(1-37) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes","volume":"67","author":"Marx","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Obesity and Psoriasis: Diabetes Meets Dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2340\/00015555-3514","article-title":"Skin Microbiome in Atopic Dermatitis","volume":"100","author":"Edslev","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/femsre\/fuw007","article-title":"Lipopolysaccharide Modification in Gram-Negative Bacteria During Chronic Infection","volume":"40","author":"Maldonado","year":"2016","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"You, M., Wang, Z., Kim, H.J., Lee, Y.H., and Kim, H.A. (2022). Pear Pomace Alleviated Atopic Dermatitis in NC\/Nga Mice and Inhibited LPS-Induced Inflammation in RAW 264.7 Macrophages. Nutr. Res. Pract., 16.","DOI":"10.4162\/nrp.2022.16.5.577"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New Insights into Atopic Dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Omotosho, I.A., Shamsuddin, N., Zaman Huri, H., Chong, W.L., and Rehman, I.U. (2025). From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146909"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Zhang, C., Kang, C., Zhu, J., He, Q., Li, H., Tong, Q., Wang, M., Zhang, L., and Xiong, X. (2024). Liraglutide Promotes Diabetic Wound Healing via Myo1c\/Dock5. Adv. Sci., 11.","DOI":"10.1002\/advs.202405987"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yue, H., Zhang, X., Zhao, Z., Gong, S., and Shao, S. (2025). Pro-Healing Impact of Liraglutide on Skin Wounds in Normoglycemic Mice. Int. Immunopharmacol., 147.","DOI":"10.1016\/j.intimp.2025.114050"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejphar.2015.06.056","article-title":"The Pro-Healing Effect of Exendin-4 on Wounds Produced by Abrasion in Normoglycemic Mice","volume":"764","author":"Bacci","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Xi, L., Du, J., Lu, Y., Xue, W., Xia, Y., Chen, T., Xiao, Y., Xu, N., Wang, Y., and Gao, J. (2025). Dulaglutide Accelerates Diabetic Wound Healing by Suppressing Nrf2-Dependent Ferroptosis in Diabetic Mice. Peptides, 185.","DOI":"10.1016\/j.peptides.2025.171366"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","article-title":"Exendin-4, a Glucagon-like Peptide-1 Analogue, Accelerates Diabetic Wound Healing","volume":"208","author":"Roan","year":"2017","journal-title":"J. Surg. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/scd.2020.0137","article-title":"Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats","volume":"30","author":"Song","year":"2021","journal-title":"Stem Cells Dev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jbiosc.2022.06.004","article-title":"Synergistic Effect of Glucagon-like Peptide-1 Analogue Liraglutide and ZnO on the Antibacterial, Hemostatic, and Wound Healing Properties of Nanofibrous Dressings","volume":"134","author":"Wu","year":"2022","journal-title":"J. Biosci. Bioeng."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic Implications of Glucagon-like Peptide-1 Receptor Agonist Medications","volume":"11","author":"Burke","year":"2025","journal-title":"Ski. Appendage Disord."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Parker, J.B., Griffin, M., Akras, D., Liang, N.E., Valencia, C., Morgan, A.G., Kuhnert, M., DiIorio, S.E., Longaker, M.T., and Wan, D.C. (2025). The Unique Roles of Adipose Tissue in Wound Healing. Adv. Wound Care, ahead of print.","DOI":"10.1177\/21621918251383812"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, Y., Long, J., Zhang, Z., and Yin, W. (2024). Insights into the Unique Roles of Dermal White Adipose Tissue (DWAT) in Wound Healing. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1346612"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Schwandt, A., Bergis, D., Dapp, A., Ebner, S., Jehle, P.M., K\u00f6ppen, S., Risse, A., Zimny, S., and Holl, R.W. (2015). Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression. J. Diabetes Res., 2015.","DOI":"10.1155\/2015\/792968"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cheng, D., Ji, H., Theodosakis, N., Noe, M.H., Chen, S.T., and Ma, K.S.-K. (2026). Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Psoriasis and Comorbid Type 2 Diabetes: A Population-Based Target Trial Emulation. J. Am. Acad. Dermatol., ahead of print.","DOI":"10.1016\/j.jaad.2026.02.008"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with Liraglutide, a Glucagon-like Peptide-1 Analogue, Improves Effectively the Skin Lesions of Psoriasis Patients with Type 2 Diabetes: A Prospective Cohort Study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaad.2025.12.035","article-title":"Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Psoriasis Is Associated with a Decreased Risk of Psoriatic Arthritis: A Retrospective Cohort Study Using the TriNetX Database","volume":"94","author":"Hsiao","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Veale, J.D., Gorman, \u00c1., Veale, D.J., Fearon, U., Orr, C., and Marzaioli, V. (2025). Investigation of Serum Biomarkers in Rheumatoid and Psoriatic Arthritis Patients for Disease-Specific Signatures. Arthritis Res. Ther., 27.","DOI":"10.1186\/s13075-025-03608-6"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of Effect of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide on Psoriasis in Glucose-tolerant Patients\u2014A Randomized Placebo-controlled Trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ced\/llaf473","article-title":"Dermatological and Metabolic Benefits of Semaglutide in Psoriasis with Obesity: A 6-Month Prospective Cohort Study","volume":"51","author":"Nicolau","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","article-title":"Improvement of Psoriasis during Exenatide Treatment in a Patient with Diabetes","volume":"38","author":"Buysschaert","year":"2012","journal-title":"Diabetes Metab."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Costanzo, G., Curatolo, S., Bus\u00e0, B., Belfiore, A., and Gullo, D. (2021). Two Birds One Stone: Semaglutide Is Highly Effective Against Severe Psoriasis in a Type 2 Diabetic Patient. Endocrinol. Diabetes Metab. Case Rep., ahead of print.","DOI":"10.1530\/EDM-21-0007"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Lee, Y.-J., Fang, Y.-W., Chen, M.-T., Liou, H.-H., Li, T.-H., and Tsai, M.-H. (2025). Association Between Autoimmune Diseases and Glucagon-like Peptide-1 Receptor Agonists: A Real-World Evidence Study. J. Autoimmun., 155.","DOI":"10.1016\/j.jaut.2025.103453"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Nowowiejska, J., Baran, A., and Flisiak, I. (2023). The First Case of the Exacerbation of Psoriatic Skin Lesions After Liraglutide. Pol. Arch. Intern. Med., 133.","DOI":"10.20452\/pamw.16527"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjd.12380","article-title":"Liraglutide in Combination with Acitretin for Severe Recalcitrant Psoriasis","volume":"169","author":"Reid","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Petkovi\u0107-Dabi\u0107, J., Bini\u0107, I., Cari\u0107, B., Bo\u017ei\u0107, L., Umi\u010devi\u0107-\u0160ipka, S., Bednar\u010duk, N., Dabi\u0107, S., \u0160itum, M., Popovi\u0107-Peji\u010di\u0107, S., and Stojiljkovi\u0107, M.P. (2025). Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules, 15.","DOI":"10.3390\/biom15010046"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the Treatment of Obesity Among Patients with Hidradenitis Suppurativa","volume":"162","author":"Nicolau","year":"2024","journal-title":"Med. Clin."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis Suppurativa: Epidemiology, Clinical Presentation, and Pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Gouvrion, L., Delage, M., Villani, A.P., Le Naour, S., Fite, C., Cassius, C., Misery, L., Oul\u00e8s, B., Fayad, A., and Brun, A. (2025). Glucagon-like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa. JAMA Dermatol., 161.","DOI":"10.1001\/jamadermatol.2025.2723"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"178","DOI":"10.36849\/JDD.9586","article-title":"GLP-1 Receptor Agonists in Overweight and Obese Patients with Hidradenitis Suppurativa","volume":"25","author":"Encarnacion","year":"2026","journal-title":"J. Drugs Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdin.2025.05.004","article-title":"Patient-Reported Outcomes of Glucagon-like Peptide-1 Agonists on Hidradenitis Suppurativa Severity","volume":"21","author":"Gupta","year":"2025","journal-title":"JAAD Int."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jabin, A., Khan, S., Khan, H., Durrani, Z.U., Hamza, K., Gul, F., Atta Ullah, S., Dayam, F., Yaseen, M., and Shah, S. (2026). The Impact of Glucagon-like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity. Cureus, 18.","DOI":"10.7759\/cureus.101212"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/ijd.70191","article-title":"Glucagon-like Peptide-1 Receptor Agonists Are Associated with Reduced Disease Severity and Pain in Hidradenitis Suppurativa: A Retrospective Study","volume":"65","author":"Islam","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jaad.2025.12.092","article-title":"Glucagon-like Peptide-1 Receptor Agonists May Decrease Biologic Initiation in Hidradenitis Suppurativa: A TriNetX Retrospective Analysis","volume":"94","author":"Kasheri","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40257-026-01014-5","article-title":"A Matched Pairs Analysis of GLP-1 Receptor Agonists in Hidradenitis Suppurativa","volume":"27","author":"Lam","year":"2026","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaad.2025.11.017","article-title":"The Impact of GLP-1 Receptor Agonists on Clinical Outcomes and Healthcare Utilization in Hidradenitis Suppurativa Patients: A Retrospective Cohort Study Using TriNetX","volume":"94","author":"Fite","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdin.2025.12.008","article-title":"GLP-1 Receptor Agonist Use in Patients with Psoriasis or Hidradenitis Suppurativa","volume":"25","author":"Granovsky","year":"2026","journal-title":"JAAD Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2025.01.013","article-title":"Update on Atopic Dermatitis","volume":"155","author":"Meledathu","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jaad.2025.08.019","article-title":"Glucagon-like Peptide-1 Receptor Agonists Mitigate the Risk of Major Adverse Cardiovascular Events in Patients with Atopic Dermatitis and Type 2 Diabetes","volume":"93","author":"Braun","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study","volume":"92","author":"Burke","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s13555-025-01640-7","article-title":"Improvement of Chronic Spontaneous Urticaria After Glucagon-like Peptide 1 Receptor Agonist Therapy: Report of Two Cases","volume":"16","author":"Kwiek","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_108","unstructured":"Mense, S.A., and Lio, P. (2024). The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis. J. Integr. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2025.09.080","article-title":"Association of Glucagon-like Peptide-1 Agonist Use with Atopic Dermatitis in Obese Patients: A Retrospective Cohort Study","volume":"94","author":"Burke","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaad.2025.04.058","article-title":"GLP-1 Agonists May Modulate Treatment Efficacy in Central Centrifugal Cicatricial Alopecia","volume":"93","author":"Desir","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Morrissette, K., Hansen, S., Pavlis, M., and Murray, J.C. (2024). Improvement of Recalcitrant Folliculitis Decalvans with Tirzepatide: A Case Report. Cureus, 16.","DOI":"10.7759\/cureus.76267"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2024.06.001","article-title":"Treatment of Insulin Resistance with Tirzepatide Leading to Improvement of Hair Loss","volume":"50","author":"Gordon","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Hill, M.A., Yang, A.C., Bergfeld, W., and Piliang, M. (2026). Impact of GLP-1 and GLP-1\/GIP Agonists on Healthcare Resource Utilization in Individuals with Scarring Alopecias: A Retrospective Cohort Analysis Using TriNetX. J. Am. Acad. Dermatol., ahead of print.","DOI":"10.1016\/j.jaad.2026.02.049"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Herrera, H.O., and Bordeaux, J.S. (2026). Risk of New-Onset Hair Loss with Semaglutide and Tirzepatide: A TriNetX Cohort Study. J. Am. Acad. Dermatol., ahead of print.","DOI":"10.1016\/j.jaad.2026.02.042"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.8605","article-title":"A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies","volume":"24","author":"Daniel","year":"2025","journal-title":"J. Drugs Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/ijd.17971","article-title":"Association Between Androgenetic Alopecia and Glucagon-like Peptide-1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study","volume":"64","author":"Singal","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10557-024-07613-w","article-title":"Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study","volume":"39","author":"Nakhla","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jaad.2023.12.073","article-title":"Treatment for Central Centrifugal Cicatricial Alopecia\u2014Delphi Consensus Recommendations","volume":"90","author":"Jackson","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1529-8019.2008.00204.x","article-title":"Folliculitis Decalvans","volume":"21","author":"Otberg","year":"2008","journal-title":"Dermatol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.abd.2022.09.006","article-title":"Female-Pattern Hair Loss: Therapeutic Update","volume":"98","author":"Melo","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender Differences in Adverse Drug Reactions: Analysis of Spontaneous Reports to a Regional Pharmacovigilance Centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_122","unstructured":"Collins, L., and Costello, R.A. (2024). Glucagon-like Peptide-1 Receptor Agonists. StatPearls, StatPearls Publishing."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 Agonist, Liraglutide, as a Pharmacotherapy for Obesity","volume":"7","author":"Crane","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, Characterization, and Clinical Development of the Glucagon-like Peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 Delivery Technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1179\/acb.2008.083","article-title":"New Therapeutic Approaches in Type 2 Diabetes","volume":"63","author":"Scheen","year":"2008","journal-title":"Acta Clin. Belg."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent Advances in Half-Life Extension Strategies for Therapeutic Peptides and Proteins","volume":"24","author":"Tan","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The Incretin System: Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_130","unstructured":"Eli Lilly and Company (2026, April 24). Trulicity (Dulaglutide) Injection, for Subcutaneous Use: Prescribing Information. Indianapolis, IN, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125469s051lbl.pdf."},{"key":"ref_131","unstructured":"Novo Nordisk (2026, April 24). Wegovy (Semaglutide) Injection, for Subcutaneous Use: Prescribing Information. Bagsv\u00e6rd, Denmark, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf."},{"key":"ref_132","unstructured":"Eli Lilly and Company (2026, April 24). Mounjaro (Tirzepatide) Injection, for Subcutaneous Use: Prescribing Information. Indianapolis, IN, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215866Orig1s002s006lbl.pdf."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes","volume":"13","author":"Deyoung","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Buckley, S.T., B\u00e6kdal, T.A., Vegge, A., Maarbjerg, S.J., Pyke, C., Ahnfelt-R\u00f8nne, J., Madsen, K.G., Sch\u00e9ele, S.G., Alanentalo, T., and Kirk, R.K. (2018). Transcellular Stomach Absorption of a Derivatized Glucagon-like Peptide-1 Receptor Agonist. Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in Oral Peptide Therapeutics","volume":"19","author":"Drucker","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hu, E.H., Tsai, M.L., Lin, Y., Chou, T.S., and Chen, T.H. (2024). A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists. Medicina, 60.","DOI":"10.3390\/medicina60030357"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., and Sun, T. (2026). Comprehensive Evaluation of GLP-1 Receptor Agonists: An Umbrella Review of Clinical Outcomes across Multiple Diseases. Nat. Commun., 17.","DOI":"10.1038\/s41467-025-67701-9"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Persson, C., Eaton, A., and Mayrovitz, H.N. (2025). A Closer Look at the Dermatological Profile of GLP-1 Agonists. Diseases, 13.","DOI":"10.3390\/diseases13050127"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Filippatos, T.D., Panagiotopoulou, T.V., and Elisaf, M.S. (2015). Adverse Effects of GLP-1 Receptor Agonists. Rev. Diabet. Stud., 11.","DOI":"10.1900\/RDS.2014.11.202"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11030-025-11195-6","article-title":"GLP-1R Agonists: Recent Advances, Current Gaps, and Future Challenges","volume":"30","author":"Saran","year":"2026","journal-title":"Mol. Divers."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Fadel, L.P., Thao, G., Chitre, T., Rojas, E.D., Fricko, M.N., Domingo, V., Budginas, B., Guerrero, L.C., Ghatas, M., and Arani, N.T. (2025). A System-Based Review on Effects of Glucagon-like Peptide-1 Receptor Agonists: Benefits vs Risks. Cureus, 17.","DOI":"10.7759\/cureus.78575"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"He, X., Zhao, Z., Sun, Y., and Jiang, X. (2025). Unraveling the Safety Profile of GLP-1 Receptor Agonists: Mechanistic Insights with a Focus on Semaglutide. Eur. J. Med. Chem., 300.","DOI":"10.1016\/j.ejmech.2025.118163"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Sonego, B., Zelin, E., Zalaudek, I., and Di Meo, N. (2023). Bullous Pemphigoid Triggered by Dulaglutide: A Case Report and a Review of the Literature. Dermatol. Rep., 15.","DOI":"10.4081\/dr.2023.9676"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.12788\/cutis.0262","article-title":"Bullous Pemphigoid Triggered by Liraglutide","volume":"107","author":"Collins","year":"2021","journal-title":"Cutis"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Karakousis, N., Kostakopoulos, N.A., Georgakopoulou, V.E., Pyrgioti, E.E., and Georgakopoulos, P.N. (2021). A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient. Cureus, 13.","DOI":"10.7759\/cureus.20041"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jvc2.255","article-title":"Hypersensitivity to Glucagon-like Peptide-1 Receptor Agonists: A Case of Delayed Urticaria-like Rash to Dulaglutide and Literature Review","volume":"3","author":"Bianchi","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.6550","article-title":"Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports","volume":"22","author":"Ouellette","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/SAP.0000000000004089","article-title":"Glucagon-like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons","volume":"94","author":"Stanton","year":"2025","journal-title":"Ann. Plast. Surg."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Haykal, D., Hersant, B., Cartier, H., and Meningaud, J.P. (2024). The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. J. Cosmet. Dermatol., 24.","DOI":"10.1111\/jocd.16716"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"K\u0131l\u0131\u00e7, S. (2025). Facial Aging after GLP-1 Receptor Agonist\u2013Induced Weight Loss: The Emerging Ozempic Face Phenomenon. J. Diabetes Metab. Disord., 24.","DOI":"10.1007\/s40200-025-01778-3"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bjps.2024.07.051","article-title":"The Rise of \u201cOzempic Face\u201d: Analyzing Trends and Treatment Challenges Associated with Rapid Facial Weight Loss Induced by GLP-1 Agonists","volume":"96","author":"Mansour","year":"2024","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00106-025-01653-w","article-title":"Rapid Weight Loss through GLP-1 Receptor Agonists as Lifestyle Phenomenon and Implications for Plastic Esthetic Medicine","volume":"73","author":"Seidel","year":"2025","journal-title":"HNO"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bjps.2023.04.057","article-title":"Ozempic Face: A New Challenge for Facial Plastic Surgeons","volume":"81","author":"Tay","year":"2023","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Duan, X., Li, R., Fu, L., Yang, J., and Zhan, Z. (2026). Advances in the Role of Adipose Tissue in Promoting Injury Repair and Resist Infection. Immun. Inflamm. Dis., 14.","DOI":"10.1002\/iid3.70341"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/605\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:25:38Z","timestamp":1779510338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":158,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["pharmaceutics18050605"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18050605","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}